BERUBICIN HYDROCHLORIDE

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C34H35NO11.ClH
Molecular Weight	670.103
Optical Activity	UNSPECIFIED
Defined Stereocenters	6 / 6
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

Cl.COC1=C2C(=O)C3=C(C(=O)C2=CC=C1)C(O)=C4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](OCC6=CC=CC=C6)[C@H](C)O5)C4=C3O)C(=O)CO

InChI

InChIKey=GPMIHHFZKBVWAZ-LMMKTYIZSA-N

InChI=1S/C34H35NO11.ClH/c1-16-33(44-15-17-7-4-3-5-8-17)20(35)11-24(45-16)46-22-13-34(42,23(37)14-36)12-19-26(22)32(41)28-27(30(19)39)29(38)18-9-6-10-21(43-2)25(18)31(28)40;/h3-10,16,20,22,24,33,36,39,41-42H,11-15,35H2,1-2H3;1H/t16-,20-,22-,24-,33+,34-;/m0./s1

HIDE SMILES / InChI

Molecular Formula	C34H35NO11
Molecular Weight	633.6418
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	6 / 6
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://gmpnews.net/2018/04/cns-pharmaceuticals-commenced-a-crowdfunding-campaign-for-its-gmb-drug/ | https://www.docguide.com/berubicin-shows-efficacy-recurrent-glioblastoma-multiforme | https://adisinsight.springer.com/drugs/800019645

Berubicin, an anthracycline derivative, is a DNA binding agent and potent topoisomerase II poison. Reata Pharmaceuticals were developing it as a treatment for brain cancer as it can breach the blood-brain barrier. It had also been in early clinical trials for the treatment of lung cancer and malignant gliomas. However, studies have been terminated. In October 2006, it was granted orphan drug designation from the FDA for the treatment of malignant gliomas. According to a CNS Pharmaceuticals media release in April 2018, berubicin will be studied for glioblastoma patients, these investigations will be funded in part by an equity crowdfunding campaign.

Originator

Approval Year

Sample Use Guides

In Vivo Use Guide

administered berubicin as a 2-hour intravenous infusion on each of the first 3 days of a 21-day cycle in 35 patients (arm A; 1.2-9.6 mg/m2) or once weekly for 4 weeks every 5 weeks in 19 patients (arm B; 7.5-13.3 mg/m2).

Route of Administration: Intravenous

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:13:51 GMT 2025` Edited by `admin` on `Mon Mar 31 18:13:51 GMT 2025`
Record UNII	7BA3X03948
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

RTA 744

Preferred Name

English

BERUBICIN HYDROCHLORIDE

Official Name

English

RTA-744

Code

English

BERUBICIN HYDROCHLORIDE [USAN]

Common Name

English

BERUBICIN HCL

Common Name

English

5,12-NAPHTHACENEDIONE, 10-((3-AMINO-2,3,6-TRIDEOXY-4-O-(PHENYLMETHYL)-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYACETYL)-1-METHOXY-, (8S,10S)-, HYDROCHLORIDE

Common Name

English

(8S,10S)-10-(((2R,4S,5S,6S)-4-AMINO-5-(BENZYLOXY)-6-METHYLTETRAHYDRO-2H-PYRAN-2-YL)OXY)-8-GLYCOLOYL-6,8,11-TRIHYDROXY-1-METHOXY-7,8,9,10-TETRAHYDROTETRACENE-5,12-DIONE HYDROCHLORIDE

Common Name

English

WP744

Code

English

Berubicin hydrochloride [WHO-DD]

Common Name

English

WP-744

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C1594